STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
Eli Lilly has achieved a significant milestone by ranking first in both innovation and invention categories in a recent pharmaceutical R&D performance index. This ranking, produced by IDEA Pharma, highlights the company's success in generating revenue from new products and its extensive drug development efforts. This is the first instance of a single company topping both categories in the index's history.
- ▪Eli Lilly ranked No. 1 in both innovation and invention categories according to IDEA Pharma.
- ▪The innovation category considers revenue from new products and drug approvals, while invention looks at drugs in development and R&D investment.
- ▪This is the first time a single company has achieved the top ranking in both categories.
Opening excerpt (first ~120 words) tap to expand
STAT PlusPharma Eli Lilly tops prominent rankings on pharma R&D performance Report by UKlooks at progress on ‘innovation’ and ‘invention’ Manage alerts for this article Email this article Share this article Eli Lilly and Company rings the opening bell of the New York Stock Exchange this month. The drug company’s labs were rated No. 1 in two key categories.ANGELA WEISS / AFP via Getty Images By Allison DeAngelis and Matthew HerperMay 19, 2026 Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
